Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options
Bibliographic Data
| ID | 22086386 |
|---|---|
| Authors | Amirah Azzeri (0000-0001-6261-1307, Universiti Sains Islam Malaysia), Maznah Dahlui (0000-0003-4923-9410, University Malaya Medical Centre), Rosmawati Mohamed (0000-0001-7595-5045, University of Malaya), Scott Mcdonald (0000-0001-9887-7481, Glasgow Caledonian University), Scott Alexander McDonald, Hafiz Jaafar (0000-0003-0467-3213, Universiti Sains Islam Malaysia), Fatiha Hana Shabaruddin (0000-0001-8153-073X, University of Malaya, corresponding author) |
| Year | 2023 |
| Volume | 11 |
| Pages | 1114560-1114560 |
| Publication date | 2023-02-22 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2023.1114560 |
| PMID | 36935675 |
| OpenAlex | W4321498483 |
| Language | EN |
| Citations received | 1 |
| References cited | 24 |
Introduction: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes but has higher drug acquisition costs compared to SOF/DAC. A stratified treatment cascade might be the most cost-efficient approach for Malaysia whereby all HCV patients are treated with SOF/DAC except for patients with cirrhosis who are treated with SOF/VEL. Methods: This study aimed to conduct a 5-year budget impact analysis of the proposed stratified treatment cascade for HCV treatment in Malaysia. A disease progression model that was developed based on model-predicted HCV epidemiology data was used for the analysis, where all HCV patients in scenario A were treated with SOF/DAC for all disease stages while in scenario B, SOF/DAC was used only for non-cirrhotic patients and SOF/VEL was used for the cirrhotic patients. Healthcare costs associated with DAA therapy and disease stage monitoring were included to estimate the downstream cost implications. Results: The stratified treatment cascade with 109 in Scenario B was found to be cost-saving compared to Scenario A. The cumulative savings for the stratified treatment cascade was USD 1.4 million over 5 years. Discussion: A stratified treatment cascade with SOF/VEL was expected to be cost-saving and can result in a budget impact reduction in overall healthcare expenditure in Malaysia
Daclatasvir · Hepatitis C virus · Liver disease · Sofosbuvir · Virus · Health Systems, Economic Evaluations, Quality of Life · Hepatitis C virus research · Medicine · Pharmaceutical Economics and Policy · Emergency Medicine · Internal Medicine · Virology
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |